Skip to main content

Biomedical Photometrics, Cellexus, IUL Instruments, Galapagos, GSK, CompuCyte, CSHL, MDS

Premium
Biomedical Photometrics Ships Imaging System Through Early-Access Program
 
Biomedical Photometrics of Waterloo, Ontario, has announced the shipment of its panoramic fluorescence imaging system to Arizona State University and other research institutions through an early-access program.
 
Initial units of the TISSUEscope platform began shipping in March of this year, and the company has begun accepting orders from other customers.
 
The TISSUEscope platform is based on patented MACROscope technology. BPI developed the prototype technology for the next-generation platform in 2005, and continued with alpha and beta testing in 2006 and early 2007. 
 

 
Cellexus Names IUL As Its Distributor
 
Cellexus Biosystems this week appointed IUL Instruments, of Königswinter, Germany, as its exclusive distributor in Austria, Benelux, Germany, the Netherlands, and Switzerland
 
IUL distributes cell-based reagents and instruments to the biotechnology and biopharmaceutical industries, covering countries from Austria to the Netherlands.
 
Financial details of the agreement were not provided.
 

 
Galapagos and GSK Expand Osteoarthritis Alliance
 
Galapagos this week announced that its existing multi-year alliance in osteoarthritis with GlaxoSmithKline will be expanded.
 
As part of the expansion, GSK has made an equity investment of €4.4 million ($5,980,000) in Galapagos by subscribing to 513,281 newly issued shares from Galapagos at €8.63 per share.
 
As part of this program expansion, Galapagos will progress a disease-modifying drug towards completion of Phase IIa clinical trials, at which point GSK’s global research and development organization will be responsible for the late-stage development, production, and marketing of the drug. In addition, GSK may add a second osteoarthritis drug discovery program against a selected GSK target into the alliance.
 

 
CompuCyte, CSHL Establish Imaging Cytometry Center of Excellence
 
CompuCyte and Cold Spring Harbor Laboratory this week announced the establishment of what they say is the first US-based Regional Quantitative Imaging Cytometry Center of Excellence.
 
Located at CSHL and jointly run by the two organizations, the center will provide educational and training resources for quantitative imaging cytometry based on CompuCyte’s laser scanning technology.
 
Under the agreement, which extends and expands an existing relationship between the two organizations, CSHL and CompuCyte will sponsor an annual symposium and several training programs throughout the year, focusing on new QIC techniques for researchers using LSC systems in cell and tissue-based research.
 

 
MDS Files to Buy Back 4.5M Shares Over 12 Months
 
MDS this week filed with the Toronto Stock Exchange to buy back up to 4.5 million of its common shares over the next 12 months.
 
The potential buyback relates to MDS’ shares that trade on the Toronto exchange and will not affect the company’s shares that trade on the New York Stock Exchange.
 
As of June 26, MDS had 122.5 million shares issued and outstanding on the Toronto Stock Exchange.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.